FDA Inspection 1179611 — Adam Gerstenblith, M.D.
The FDA completed an inspection of Adam Gerstenblith, M.D. on September 2, 2022 in Hagerstown, MD. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- September 2, 2022
- Fiscal Year
- 2022
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Hagerstown, MD (United States)
Additional Details
Clinical Investigator (CI)